Publications
Detailed Information
Intracoronary versus intravenous glycoprotein IIb/IIIa inhibitors during primary percutaneous coronary intervention in patients with STEMI: a systematic review and meta-analysis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Hahn, JongSung | - |
dc.contributor.author | Jeon, Jinyoung | - |
dc.contributor.author | Geum, Min Jung | - |
dc.contributor.author | Lee, Hyun Woo | - |
dc.contributor.author | Shin, Jaekyu | - |
dc.contributor.author | Chung, Woo-Young | - |
dc.contributor.author | Yu, Yun Mi | - |
dc.contributor.author | Ah, Young-Mi | - |
dc.date.accessioned | 2023-08-11T01:55:06Z | - |
dc.date.available | 2023-08-11T10:55:32Z | - |
dc.date.issued | 2023-07-14 | - |
dc.identifier.citation | Thrombosis Journal Vol.21(1):76 | ko_KR |
dc.identifier.issn | 1477-9560 | - |
dc.identifier.uri | https://hdl.handle.net/10371/195350 | - |
dc.description.abstract | Background Intracoronary (IC) administration of glycoprotein IIb/IIIa inhibitors (GPIs) has been studied as an
adjunctive therapy to improve outcomes in patients with ST-segment elevation myocardial infarction (STEMI) undergoing percutaneous coronary intervention. In this systematic review and meta-analysis, we aimed to evaluate the efficacy and safety of IC administration of GPIs compared with those of intravenous (IV) administration in patients with STEMI. Methods We searched the MEDLINE, Embase, and Cochrane CENTRAL databases for relevant studies published before September 21, 2022. In total, 22 randomized controlled trials involving 7,699 patients were included. Results The proportions of patients achieving thrombolysis in myocardial infarction grade 3 flow, myocardial blush grade 2/3, and complete ST-segment resolution were significantly higher in the IC group than in the IV group. Major adverse cardiac events (MACE) (RR: 0.54, 95% CI: 0.37–0.80) and heart failure (RR: 0.48, 95% CI: 0.25–0.91) within 1 month were significantly lower in the IC group than in the IV group; however, after 6 months, no difference was observed in MACE risk. Additionally, the risks of death and bleeding did not differ between the two routes of administration. Conclusions When considering adjunctive GPI administration for patients with STEMI, the IC route may offer greater benefits than the IV route in terms of myocardial reperfusion and reduced occurrence of MACE and heart failure within 1 month. Nonetheless, when making decisions for IC administration of GPIs, the absence of a benefit for bleeding risk and difficulty accessing the administration route should be considered | ko_KR |
dc.language.iso | en | ko_KR |
dc.publisher | BMC | ko_KR |
dc.subject | s ST-elevation myocardial infarction | - |
dc.subject | Percutaneous coronary intervention | - |
dc.subject | Glycoprotein IIb/IIIa inhibitor | - |
dc.subject | Intracoronary administration | - |
dc.title | Intracoronary versus intravenous glycoprotein IIb/IIIa inhibitors during primary percutaneous coronary intervention in patients with STEMI: a systematic review and meta-analysis | ko_KR |
dc.type | Article | ko_KR |
dc.identifier.doi | 10.1186/s12959-023-00519-x | ko_KR |
dc.citation.journaltitle | Thrombosis Journal | ko_KR |
dc.language.rfc3066 | en | - |
dc.rights.holder | The Author(s) | - |
dc.date.updated | 2023-07-16T03:11:09Z | - |
dc.citation.number | 1 | ko_KR |
dc.citation.volume | 21 | ko_KR |
- Appears in Collections:
- Files in This Item:
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.